Pfizer (PFE) stock price slips before the bell after obesity-drug update, 2026 outlook
Pfizer shares slipped roughly 3.4% to $25.77 during Wednesday's U.S. premarket session.
Eli Lilly (LLY) stock price jumps 10% after 2026 outlook; pricing pressure and FDA decision in focus
Eli Lilly and Company shares surged about 10% Wednesday after the company released its quarterly earnings and 2026 outlook, sparking renewed enthusiasm for its weight-loss division. The stock climbed to $1,104.94 in late-morning New York trading, bouncing back from a low of $995.88 earlier in the session.
Eli Lilly stock in focus before earnings after Novo warns on obesity-drug price squeeze
Eli Lilly shares dipped slightly in premarket trading Wednesday, following a steep decline the day before that thrust the drugmaker back into focus in the obesity-drug sector. The stock was down roughly 0.5% at $998.50, after closing Tuesday at $1,003.21, slipping nearly 4%.
Novo Nordisk stock price sinks nearly 18% as 2026 outlook jolts Wegovy trade
Novo Nordisk A/S shares dropped roughly 18% in early Copenhagen trading Wednesday, last seen near 302.5 Danish crowns. The decline followed the drugmaker’s 2026 outlook, which hinted at a steep slowdown in its weight-loss business.
Novo Nordisk stock hammered as Ozempic maker warns 2026 sales may fall up to 13%
Novo Nordisk shares dropped sharply on Wednesday after the Danish pharmaceutical giant flagged a potential 13% decline in sales and profit for 2026, marking a notable reversal for the company behind weight-loss drug Wegovy and diabetes treatment Ozempic. Early trading in Copenhagen saw shares plunge 18%, according to the Financial Times. https://www.ft.com/content/d148ce25-fa76-468b-b9ac-95c62a994a55
GSK stock swings after earnings as new CEO Luke Miels sets softer 2026 outlook
GSK shares recovered on Wednesday following the release of new CEO Luke Miels’ first sales forecast, which showed slower growth for 2026—a key test investors had been eyeing. After an early dip of roughly 1%, the stock climbed 1.4% by 0809 GMT.
GSK beats 2025 sales targets — but new CEO warns 2026 growth will cool
GSK is projecting slower sales growth in 2026 under new CEO Luke Miels, who took over from Emma Walmsley earlier this year. The company is bracing for patent expiries on its leading HIV drugs starting in 2028. It now expects revenue growth of 3% to 5% at constant currency, while warning that vaccines and general medicines sales might decline. Shares climbed 1.4% by 0809 GMT after an initial drop. Core earnings per share for Q4 came in at 25.5 pence, supported by an 8% sales increase to £8.62 billion.
Johnson & Johnson stock price rises after RBC target hike as investors eye talc risk, new data
Johnson & Johnson shares climbed roughly 1% on Tuesday following an upgrade from RBC Capital Markets, which lifted its price target and kept focus on the company’s ongoing legal issues. The stock last traded at $233.10, fluctuating between $230.00 and $235.24, with about 9.3 million shares changing hands.
Pfizer stock slides on obesity drug data, earnings; what PFE investors watch next
Pfizer Inc shares dropped roughly 3.5% to $25.77 on Tuesday as investors absorbed fresh data on its weight-loss drug alongside the company’s latest quarterly earnings.
Merck stock price rises after hours after choppy day — MRK traders focus on 2026 outlook and FDA dates
Merck & Co shares climbed 2.2% in after-hours trading Tuesday, closing at $115.84. During the session, the stock fluctuated between $109.02 and $118.35.
Eli Lilly stock price drops 4% as Novo outlook jars weight-loss trade ahead of earnings
Eli Lilly and Company shares dropped 3.9%, closing at $1,003.46 on Tuesday, then held steady in after-hours trading. Novo Nordisk’s U.S.-listed shares plunged 14%, after it forecast a steeper sales decline than expected for 2026, weighing on the obesity-drug sector. Pfizer also slipped following new weight-loss drug data. “Novo’s showing there’s a market for oral options,” noted Citizens analyst Jonathan Wolleben.
Pfizer stock drops after obesity-drug data, even as 2026 outlook holds
Pfizer Inc. shares dropped 3.3% to $25.79 by mid-afternoon, as investors digested new weight-loss drug data alongside an unchanged 2026 forecast.
Merck stock rises despite cautious 2026 outlook as patent losses loom
Merck shares climbed around 3.1% to $116.86 in midday trading Tuesday, despite the drugmaker warning its 2026 outlook would fall short of Wall Street expectations due to patent expirations on older drugs.
Novo Nordisk warns 2026 sales could fall — and the Wegovy pill isn’t saving the mood yet
Novo Nordisk on Tuesday forecast a fall in 2026 sales and operating profit on an adjusted basis, pushing its U.S.-listed shares down about 12% in afternoon trade.
Eli Lilly stock slips as obesity-drug price cuts and rival data set up Feb. 4 earnings
Shares of Eli Lilly and Company dropped 1.4% to $1,029.99 by midday Tuesday, sliding from a session peak of $1,048.71 and dipping as low as $1,016.15.
Pfizer stock drops on obesity-drug data and 2026 outlook — what investors watch next
Pfizer dropped 3.4% to $25.76 early Tuesday, following the release of its quarterly results alongside new data on its obesity drug. By mid-morning, roughly 31 million shares had traded hands.
GSK share price nears a one-year high ahead of earnings after Wave drug handback and R&D cuts
GSK shares nudged higher in early trading Tuesday, hovering close to a one-year peak ahead of the British drugmaker’s earnings report. The stock gained 0.1% to 1,926.5 pence, after touching 1,928.5 pence earlier.
AbbVie stock gains ahead of earnings; ABBV investors brace for guidance and a $1.3 billion expense
AbbVie shares climbed $2.69, or 1.2%, on Monday, settling at $225.70 after hitting a session high of $229.80.
Merck stock rises ahead of earnings: MRK traders eye guidance and the Keytruda cliff
Merck & Co shares climbed roughly 2.2% on Monday, pushing the price up to $112.67 by midday. During the session, the stock fluctuated between $109.80 and $112.74.
Johnson & Johnson stock rises as new Erleada survival data lands
Johnson & Johnson shares rose on Monday after the company released fresh data on its prostate cancer drug Erleada, adding to a steady bid for large healthcare names in a firm U.S. market.
TechStock² Updates
